Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Debra F. Eisenberg, PhD, MS
Articles
Rehospitalizations and Direct Medical Costs for cSSSI: Linezolid Versus Vancomycin
C. Daniel Mullins, PhD;H. Keri Yang, PhD, MPH;Eberechukwu Onukwugha, PhD, MS;Debra F. Eisenberg, PhD, MS;Daniela E. Myers, MPH;David B. Huang, MD, PhD;Thomas Lodise, PharmD, PhD
December 13th 2013Among commercially insured patients treated with linezolid or vancomycin following cSSSI-related hospitalization, linezolid was associated with significantly lower rehospitalization rates and total direct medical costs.
Read More
Latest Updated Articles
Published: June 12th 2025 | Updated: June 16th 2025
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential Biomarkers
Published: June 10th 2025 | Updated: June 12th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting Members
Published: June 2nd 2025 | Updated: June 11th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular Care
Published: June 3rd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape
Published: May 30th 2025 | Updated: June 5th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201
Published: April 18th 2025 | Updated: April 21st 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders
